Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective $\alpha_{1A}$-adrenergic receptor antagonist. It selectively inhibits receptors in the human prostate, leading to relaxation of smooth muscle in the bladder neck and prostate, thereby improving urine flow.
## Primary Indications
* Signs and symptoms of benign prostatic hyperplasia (BPH).
* Off-label: Medical expulsive therapy for distal ureteral stones.
## Adult Dosing
* **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day.
* If no response after 2–4 weeks, the dose may be increased to 0.8 mg once daily.
* **Maximum Dose:** 0.8 mg daily.
## Pediatric Dosing
Tamsulosin is not indicated for pediatric use. Safety and efficacy in children have not been established. Use is generally avoided unless managed by a specialized pediatric urologist.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment indicated for mild to moderate impairment. Use caution in severe renal impairment (CrCl <10 mL/min).
* **Hepatic Impairment:** No dosage adjustment in mild to moderate impairment. Use caution in severe hepatic impairment (Child-Pugh Class C); generally avoided.
## Contraindications
* Hypersensitivity to tamsulosin or any component of the formulation.
* Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin).
## Adverse Effects
* **Common:** Orthostatic hypotension, dizziness, headache, abnormal ejaculation (retrograde ejaculation), rhinitis, and fatigue.
* **Serious:** Syncope (especially with the first dose or dose escalation), priapism, and Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery.
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors:** May significantly increase tamsulosin exposure (avoid).
* **Other $\alpha$-blockers:** Increased risk of severe hypotension when combined.
* **PDE-5 Inhibitors (e.g., sildenafil, tadalafil):** Potential for additive hypotensive effects; monitor blood pressure.
* **Antihypertensives:** Potential for additive blood pressure lowering.
## Monitoring
* Baseline and periodic blood pressure (sitting and standing) to assess for orthostasis.
* Monitor for symptomatic improvement (e.g., AUA Symptom Score).
* Assess for ocular symptoms prior to planned cataract surgery.
## Clinical Pearls
* **Administration:** Must be taken 30 minutes after the same meal daily to ensure consistent bioavailability. Swallow capsules whole; do not crush, chew, or open.
* **Syncope Risk:** Advise patients to rise slowly from a sitting or lying position, especially during initiation or dose escalation.
* **Surgery:** Alert ophthalmologists if the patient is on tamsulosin before cataract surgery due to the risk of IFIS.
* **Sulfa Allergy:** While structurally a sulfonamide, clinical evidence suggests low risk of cross-reactivity in patients with "sulfa" allergies; however, monitor closely if highly sensitive.
***
*Disclaimer: This information is for educational purposes only. Drug dosing, contraindications, and interaction profiles can change. Always consult your current prescribing information, institutional protocols, and clinical pharmacy resources (e.g., Lexicomp or Micromedex) before initiating therapy.*
